Alternative transporter pathways in patients with untreated early-stage and late-stage primary biliary cirrhosis

Liver International

Volumn 29, Issue 3, 2009, Pages 406-414

  Takeyama, Yasuaki ^a   Uehara, Yuko ^a   Inomata, Shinjiro ^a   Morihara, Daisuke ^a   Nishizawa, Shinya ^a   Ueda, Shu Ichi ^a   Matsumoto, Teruo ^a   Tanaka, Takashi ^a   Anan, Akira ^a   Nishimura, Hirokatsu ^a   Irie, Makoto ^a   Iwata, Kaoru ^a   Shakado, Satoshi ^a   Sohda, Tetsuro ^a   Sakisaka, Shotaro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

MRP2; MRP3; MRP4; Multidrug resistance protein; Nuclear hormone receptor; PBC; Primary biliary cirrhosis

Indexed keywords

ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; FETOPROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; NUCLEAR FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; LIVER; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

BLOTTING, SOUTHWESTERN; CARRIER PROTEINS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MEMBRANE GLYCOPROTEINS; MICROSCOPY, FLUORESCENCE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OLIGONUCLEOTIDE PROBES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 59849105277     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01846.x     Document Type: Article

References (36)

1. Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations. Mol Pharm 2006; 3: 231-51.
2. Ogawa K, Suzuki H, Hirohashi T, et al. Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol 2000; 278: G438-46.
3. Tanaka Y, Kobayashi Y, Gabazza EC, et al. Increased renal expression of bilirubin glucuronide transporters in a rat model of obstructive jaundice. Am J Physiol Gastrointest Liver Physiol 2002; 282: G656-62.
4. Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001; 34: 351-9.
5. Shoda J, Kano M, Oda K, et al. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am J Gastroenterol 2001; 96: 3368-78.
6. Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz J, Boyer JL. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 2004; 40: 585-91.
7. Lee J, Azzaroli F, Wang L, et al. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 2001; 121: 1473-84.
8. Soroka CJ, Lee JM, Azzaroli F, Boyer JL. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 2001; 33: 783-91.
9. Denson LA, Bohan A, Held MA, Boyer JL. Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis. Gastroenterology 2002; 123: 599-607.
10. Bohan A, Chen WS, Denson LA, Held MA, Boyer JL. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem 2003; 278: 36688-98.
11. Kitada H, Miyata M, Nakamura T, et al. Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. J Biol Chem 2003; 278: 17838-44.
12. Wagner M, Fickert P, Zollner G, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003; 125: 825-38.
13. Keitel V, Burdelski M, Warskulat U, et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 2005; 41: 1160-72.
14. Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol 2006; 290: G640-9.
15. Assem M, Schuetz EG, Leggas M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004; 279: 22250-7.
16. Stedman CA, Liddle C, Coulter SA, et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci USA 2005; 102: 2063-8.
17. Karpen SJ. Nuclear receptor regulation of hepatic function. J Hepatol 2002; 36: 832-50.
18. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004; 126: 322-42.
19. Anwer MS. Cellular regulation of hepatic bile acid transport in health and cholestasis. Hepatology 2004; 39: 581-90.
20. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967; 60: 1257-60.
21. Shin M, Hishikawa Y, Izumi S, Koji T. Southwestern histochemistry as a molecular histochemical tool for analysis of expression of transcription factors: Application to paraffin-embedded tissue sections. Med Electron Microsc 2002; 35: 217-24.
22. Koji T, Nakane PK. Recent advances in molecular histochemical techniques: In situ hybridization and southwestern histochemistry. J Electron Microsc 1996; 45: 119-27.
23. Zollner G, Fickert P, Silbert D, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003; 38: 717-27.
24. Zollner G, Wagner M, Fickert P, et al. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 2007; 27: 920-9.
25. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476-85.
26. Zollner G, Fickert P, Fuchsbichler A, et al. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol 2003; 39: 480-8.
27. Kojima H, Nies AT, König J, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 2003; 39: 693-702.
28. Kullak-Ublick GA, Baretton GB, Oswald M, Renner EL, Paumgartner G, Beuers U. Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol Res 2002; 23: 78-82.
29. König J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999; 29: 1156-63.
30. Mennone A, Soroka CJ, Cai SY, et al. Mrp4-/-mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 2006; 43: 1013-21.
31. Boyer JL, Trauner M, Mennone A, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1124-30.
32. Cai SY, Boyer JL. FXR: A target for cholestatic syndromes? Expert Opin Ther Targets 2006; 10: 409-21.
33. Boyer JL. New perspectives for the treatment of cholestasis: Lessons from basic science applied clinically. J Hepatol 2007; 46: 365-71.
34. Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003; 112: 1678-87.
35. Shoda J, Miura T, Utsunomiya H, et al. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatology 2004; 39: 167-78.
36. Zelcer N, Wetering K, Waart R, et al. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 2006; 44: 768-75.